Reported results
- Cash and cash equivalents were $1.9 million at September 30, 2026.
- Research and development expenses were $3.7 million for the 3 months ended September 30, 2026, compared to $5.0 million for the 3 months ended September 30, 2025.
- General and administrative expenses were $2.0 million for the 3 months ended September 30, 2026, compared to $1.6 million for the 3 months ended September 30, 2025.
- The Parkview loan facility contributed $5.6 million in non-dilutive financing during the quarter ended September 30, 2026.
- Total common shares outstanding were approximately 65.8 million at September 30, 2026.
Guidance
- IFx-2.0: Expect to receive orphan drug designation in MCC in 2H 2026.
- IFx-2.0: Expect preliminary results from front-line study with Keytruda in 1H 2027.
- IFx-2.0: Expect to complete enrollment in Phase 3 registrational front-line study in 2H 2027.
- TBS-2025: Expect to initiate a Phase 1b/2 trial in mut NPM1 r/r AML in 2H 2026.
- TBS-2025: Expect to receive orphan drug designation in AML in 1H 2027.
- TBS-2025: Expect preliminary safety and response data in mutated NMP1 r/r AML in 1H 2027.
- MDSC Inhibitors: Presentations at ASH in 2H 2026.
- MDSC Inhibitors: Initiation of ADC in vivo POC studies in 2H 2026.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.
